FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897518674> ?p ?o ?g. }

• W2897518674 endingPage "viii365" @default.
• W2897518674 startingPage "viii365" @default.
• W2897518674 abstract "Background: Triple drug regimens are standard of care in newly diagnosed Multiple Myeloma (MM). Studies show 4 drug regimens to be highly active. In an economically backward country like India, newer drugs and Autologous transplant may not always be feasible because of financial constraints. We studied the effect of adding Pegylated Liposomal Doxorubicin (PLD) to standard regimen on the Response Rates (RR). Methods: 60 newly diagnosed cases of MM were included in this double armed prospective, observational, comparative study. Patients were randomly assigned into 2 arms (30 Patients in each arm). Arm A consisted of VTd regimen (Inj. Bortezomib Day (D)1, D8, D15, D22 1.3mg/ / m2, Tab. Thalidomide Daily 100mg, Inj. Dexamethasone D1, D8, D15, D22 40 mg / once in 28 days). Arm B consisted of VTdD regimen (PLD D1 i.v 30mg / m2 + VTd). Hematological and biochemical parameters were noted at baseline and after completion of 4 cycles. Response assessment was done as per the criteria defined by International Myeloma Working Group (IMWG). The outcomes between the two treatment arms in terms of RR were compared. Results:Table: 1023PRRVTdVTdDOverall Response Rates86.6%93.3%>very good partial response73.3%86.6%Stringent Complete Response33.3%53.3% Open table in a new tab The differences in sCR rates were clinically very significant. However, on application of Pearson chi-square test significance p of 0.118 was seen, which maybe attributed to the lower power of the study. Poorest responses noted were highest in the 71-80 age group. Both the regimens were equally effective in ISS B patients. Neutropenia, thrombocytopenia, infections, mucositis, edema, dizzininess/somnolence and DVT were not significantly different between the two arms (P > 0.05). Palmar–plantar erythrodysesthesia (PPE) was the only new complication seen in (10%) VTdD group. Grade 3–4 toxicities were similar in both arms. Conclusions: The role of liposomal doxorubicin in first line setting as a 4th agent along with triple drug regimen in treatment of MM looks promising, especially in countries with financial constraints for the newer drugs. Larger studies are needed to validate this. Legal entity responsible for the study: Scientific and Ethics Committee at HCG Hospital, Bangalore, India. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
• W2897518674 created "2018-10-26" @default.
• W2897518674 creator A5027333293 @default.
• W2897518674 creator A5068290637 @default.
• W2897518674 creator A5070451006 @default.
• W2897518674 creator A5089643998 @default.
• W2897518674 date "2018-10-01" @default.
• W2897518674 modified "2023-09-27" @default.
• W2897518674 title "Role of liposomal doxorubicin as a first line agent with VTd regimen in newly diagnosed multiple myeloma" @default.
• W2897518674 doi "https://doi.org/10.1093/annonc/mdy286.018" @default.
• W2897518674 hasPublicationYear "2018" @default.
• W2897518674 type Work @default.
• W2897518674 sameAs 2897518674 @default.
• W2897518674 citedByCount "0" @default.
• W2897518674 crossrefType "journal-article" @default.
• W2897518674 hasAuthorship W2897518674A5027333293 @default.
• W2897518674 hasAuthorship W2897518674A5068290637 @default.
• W2897518674 hasAuthorship W2897518674A5070451006 @default.
• W2897518674 hasAuthorship W2897518674A5089643998 @default.
• W2897518674 hasBestOaLocation W28975186741 @default.
• W2897518674 hasConcept C126322002 @default.
• W2897518674 hasConcept C141071460 @default.
• W2897518674 hasConcept C143998085 @default.
• W2897518674 hasConcept C2776364478 @default.
• W2897518674 hasConcept C2777478702 @default.
• W2897518674 hasConcept C2779609412 @default.
• W2897518674 hasConcept C2781413609 @default.
• W2897518674 hasConcept C71924100 @default.
• W2897518674 hasConcept C90924648 @default.
• W2897518674 hasConceptScore W2897518674C126322002 @default.
• W2897518674 hasConceptScore W2897518674C141071460 @default.
• W2897518674 hasConceptScore W2897518674C143998085 @default.
• W2897518674 hasConceptScore W2897518674C2776364478 @default.
• W2897518674 hasConceptScore W2897518674C2777478702 @default.
• W2897518674 hasConceptScore W2897518674C2779609412 @default.
• W2897518674 hasConceptScore W2897518674C2781413609 @default.
• W2897518674 hasConceptScore W2897518674C71924100 @default.
• W2897518674 hasConceptScore W2897518674C90924648 @default.
• W2897518674 hasLocation W28975186741 @default.
• W2897518674 hasOpenAccess W2897518674 @default.
• W2897518674 hasPrimaryLocation W28975186741 @default.
• W2897518674 hasRelatedWork W1972519999 @default.
• W2897518674 hasRelatedWork W2013163224 @default.
• W2897518674 hasRelatedWork W2112489854 @default.
• W2897518674 hasRelatedWork W2427804748 @default.
• W2897518674 hasRelatedWork W2552807483 @default.
• W2897518674 hasRelatedWork W2559593973 @default.
• W2897518674 hasRelatedWork W2988379501 @default.
• W2897518674 hasRelatedWork W3022132370 @default.
• W2897518674 hasRelatedWork W3031718141 @default.
• W2897518674 hasRelatedWork W32729895 @default.
• W2897518674 hasVolume "29" @default.
• W2897518674 isParatext "false" @default.
• W2897518674 isRetracted "false" @default.
• W2897518674 magId "2897518674" @default.
• W2897518674 workType "article" @default.